Company: AZN
Filing Date: 2025-10-22
Form Type: 6-K
Source: 0001654954-25-012040
Chunk: 6

Company: ASTRAZENECA PLC
Filing Date: 2025-10-22
Form: 6-K
Chunk 6
---
-4457-b15f-9f28545ad63a/e306dc06-d580-4457-b15f-9f28545ad63a_viewable_rendition__v.pdf . Accessed: October 2025.

11. Tezspire (tezepelumab) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/tezspire-epar-product-information_en.pdf . Accessed: October 2025.

12. AstraZeneca news release. Tezspire approved in Japan for the treatment of severe asthma. Available at: https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-approved-in-japan-for-severe-asthma.html . Accessed: October 2025.

13. Jong-Gyun J, et al. Unraveling the Role of Epithelial Cells in the Development of Chronic Rhinosinusitis. Int J Mol Sci. 2023;24(18):14229.

14. Corren J, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med . 2017;377:936-946.

15. Varricchi G, et al. Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer. Front Immunol . 2018;9:1595.

16. Xolair (omalizumab) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/xolair-epar-product-information_en.pdf . Accessed: October 2025.

17. Xolair (omalizumab) US prescribing information. Available at: https://www.gene.com/download/pdf/xolair_prescribing.pdf . Accessed: October 2025.

18. Nucala (mepolizumab) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf . Accessed: October 2025.

19. Nucala (mepolizumab) US prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761122s006,125526s018lbl.pdf . Accessed: October 2025.

20. Dupixent (dupilumab) Summary of Product Characteristics.